HIGH DOSE IFN ALFA-2B ADJUVANT THERAPY OF HIGH-RISK RESECTED CUTANEOUS MELANOMA. RESULTS AFTER 31 MONTHS MEDIAN FOLLOW-UP

被引：0
|
作者：
Muggiano, A. [1 ]
Mulas, C. [1 ]
Fiori, B. [1 ]
Liciardi, G. [1 ]
Pintus, M. [1 ]
Tanca, L. [1 ]
Tedde, A. [1 ]
Turno, R. [1 ]
Desogus, A. [1 ]
机构：
[1] Osped Oncolog A Businco, Div Med Oncol 1, Cagliari, Italy
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [21] Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma
    Mitchell, Malcolm S.
    Abrams, Judith
    Thompson, John A.
    Kashani-Sabet, Mohammed
    DeConti, Ronald C.
    Hwu, Wen-Jen
    Atkins, Michael B.
    Whitman, Eric
    Ernstoff, Marc S.
    Haluska, Frank G.
    Jakowatz, James G.
    Das Gupta, Tapas K.
    Richards, Jon M.
    Samlowski, Wolfram E.
    Costanzi, John J.
    Aronson, Frederick R.
    Deisseroth, Albert B.
    Dudek, Arkadiusz Z.
    Jones, Vicky E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 2078 - 2085
  • [22] Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma
    Levesque, N.
    Mitchinson, K.
    Lawrie, D.
    Fedorak, L.
    MacDonald, D.
    Normand, C.
    Pouliot, J. F.
    CURRENT ONCOLOGY, 2008, 15 (01) : 36 - 41
  • [23] Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
    Hansson, Johan
    Aamdal, Steinar
    Bastholt, Lars
    Brandberg, Yvonne
    Hernberg, Micaela
    Nilsson, Bo
    Stierner, Ulrika
    von der Maase, Hans
    LANCET ONCOLOGY, 2011, 12 (02): : 144 - 152
  • [24] Quality-of-life - adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group Study
    Cole, BF
    Gelber, RD
    Kirkwood, JM
    Goldhirsch, A
    Barylak, E
    Borden, E
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2666 - 2673
  • [25] A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma
    Gogas, H.
    Dafni, U.
    Bafaloukos, D.
    Polyzos, A.
    Kokkalis, G.
    Kalofonos, H. P.
    Fountzilas, G.
    Skarlos, D.
    Tsoutsos, D.
    Pectasides, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma
    Lian, Bin
    Mao, Li Li
    Cui, Chuan Liang
    Chi, Zhi Hong
    Si, Lu
    Sheng, Xi Nan
    Li, Si Ming
    Tang, Bi Xia
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Imatinib therapy after resection of high-risk gastrointestinal stromal tumors in Chinese patients: a median follow-up of 48 months
    Lei, Cheng
    Zhao, Bing
    Wang, Qisan
    Ge, Lei
    Wang, Haijiang
    JOURNAL OF BUON, 2018, 23 (02): : 460 - 467
  • [28] High-risk cutaneous melanoma follow-up: time for more intensive surveillance?
    Davidson, Michael
    Lorigan, Paul
    Larkin, James
    MELANOMA MANAGEMENT, 2014, 1 (01) : 7 - 10
  • [29] High dose IFN-α2b in high risk melanoma. Toxicity and survival study
    Gonzalez-Larriba, Jose Luis
    Alonso, A.
    Lizon, J.
    Espinosa, E.
    Crespo, C.
    Loboff, B.
    Garcia, S.
    Diaz, E.
    ANNALS OF ONCOLOGY, 2004, 15 : 202 - 202
  • [30] Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels
    Pia Vihinen
    Taina Tervahartiala
    Timo Sorsa
    Johan Hansson
    Lars Bastholt
    Steinar Aamdal
    Ulrika Stierner
    Seppo Pyrhönen
    Kari Syrjänen
    Johan Lundin
    Micaela Hernberg
    Cancer Immunology, Immunotherapy, 2015, 64 : 173 - 180
12345